07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Kotobuki, Shionogi deal

Kotobuki granted Shionogi exclusive, worldwide rights to develop and commercialize cholesterol absorption inhibitor KT6-971 . Kotobuki will receive an upfront payment and is eligible for milestones and royalties. Shionogi declined to disclose financial details, while...
01:29 , Oct 2, 2012 |  BC Extra  |  Company News

Kotobuki, Shionogi in deal for cholesterol absorption inhibitor

Kotobuki Pharmaceutical Co. (Tokyo, Japan) granted Shionogi & Co. Ltd. (Osaka, Japan) worldwide rights to develop and commercialize cholesterol absorption inhibitor KT6-971 . Kotobuki will receive an upfront payment and is eligible for milestones and...